DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
2 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
3 Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market? Visit Post
4 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
5 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
6 Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents' DrugSorb-ATR; Fujifilm-Lunit collaboration Visit Post
7 New Approaches and Evolutions to Reshape the Diabetes Management and Care Visit Post
8 Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR Visit Post
9 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
10 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
11 Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market Visit Post
12 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
13 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
14 Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future Visit Post
15 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
16 Understanding The Increasing Prevalence Of Diabetes And Its Complications Visit Post
17 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
18 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
19 Diagnosing At-Home: Are At-Home Diagnostic Tools The New Trends? Visit Post
20 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
21 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
22 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
23 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
24 The Obesity Pandemic: What can we do about it? Visit Post
25 A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Visit Post
26 Treating Patients with Software: Digital Therapeutics Visit Post
27 Will Wearable Devices be Streamlined in Healthcare? Visit Post
28 Creating Future of MedTech Industry with Artificial Intelligence Visit Post
29 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
30 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
31 What Does The Acromegaly Pipeline Have Up In Its Sleeve? Visit Post
32 What are the Top Five Leading Causes of Deaths in the World? Visit Post
33 Metabolic Acidosis: Counting The Unmeasured Anions And Closing the Gap In Blood Serum Visit Post
34 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
35 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
36 Precision Medicine: An emerging approach to conventional treatment Visit Post
37 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
38 Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities Visit Post
39 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
40 Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies Visit Post
41 Bioelectronic Medicine: Applications and Future Prospects Visit Post
42 Dubai: A leading and exciting pharma hotspot Visit Post
43 Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players Visit Post
44 Potential of Digital therapeutics and increasing CVDs Visit Post
45 Thyroid awareness month Visit Post
46 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
47 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
48 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
49 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
50 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
51 World Diabetes Day | 2019 Visit Post
52 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
53 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
54 First oral GLP-1 treatment approved for type2 Diabetes Visit Post
55 Hyperthyroidism Treatment Market and Drugs Visit Post
56 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
57 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
58 Diabetic Gastroparesis Market Outlook Visit Post
59 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
60 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
61 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
62 Teplizumab delays the progression of Type 1 Diabetes Visit Post
63 European Commission gives a nod to Zynquista for type 1 diabetes in adults Visit Post
64 Notizia Visit Post
65 Notizia Visit Post
66 AgomAb Therapeutics raises $23.5M; Allergan's eye drug; Good news for the patients; Dyne Therapeutics comes to life Visit Post
67 Notizia Visit Post
68 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
69 Human cells reprogrammed to create insulin in diabetic mice Visit Post
70 Acromegaly Visit Post
71 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
72 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
73 Notizia Visit Post
74 World Diabetes Day | 2018 Visit Post
75 World Diabetes Day Visit Post
76 Notizia Visit Post
77 Notizia Visit Post
78 Notizia Visit Post
79 Notizia Visit Post
80 SNIPPET Visit Post
81 Notizia Visit Post
82 Commercial Visit Post
83 Digital Pill: A new frontier in digital healthcare all set to take-off Visit Post
84 Commercial Visit Post
85 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
86 Nonalcoholic Steatohepatitis (NASH): Highly Epidemic Visit Post
87 Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH) Visit Post
88 Business Cocktail Visit Post
89 Notizia Visit Post
90 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
91 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
92 Business CockTail Visit Post
93 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
94 Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches Visit Post
95 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
96 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
97 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
98 Acromegaly and Gigantism: It’s all about excessive Growth Hormone… Visit Post
99 A Probiotic drink from the gut microbiome of an elite athlete Visit Post
100 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
101 Cushing’s Syndrome: Cortisol Plethora Visit Post
102 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
103 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
104 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
105 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
106 Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan's MAA accepted; Pricing hit pharma Visit Post
107 Biosimilar Market in India Visit Post
108 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
109 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
110 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
111 Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
112 Small interfering RNA (siRNA) Therapeutics Visit Post
113 DelveInsight’s Metabolic disorders based Gene Therapy Reports Visit Post
114 EMA Biosimilars Approvals Visit Post